Lantheus Holdings (LNTH) Financials: History & Chart

Lantheus Holdings, Inc.(LNTH)

Drug Manufacturers - Specialty & Generic · Bedford, MA

$99.91-0.28 (-0.28%)

Delayed quote: Oct 6, 2026, 1:30 PM EDT

About Lantheus Holdings, Inc.

Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. Their mission is to empower clinicians worldwide in the accurate diagnosis and effective treatment of a wide spectrum of conditions, particularly heart disease, various cancers, and other serious illnesses. Their current diagnostic portfolio features several key products: DEFINITY, a microbubble ultrasound contrast agent for cardiac evaluations; TechneLite, a technetium generator essential for nuclear medicine; Xenon-133, used to assess pulmonary function; Neurolite, which helps identify stroke-damaged areas in the brain; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 for detecting cardiovascular disease; and Gallium-67, utilized in identifying infections and cancerous tumors. They also offer the Automated Bone Scan Index, a tool for quantifying prostate cancer burden from bone scans; PYLARIFY, designed for visualizing lymph nodes, bone, and soft tissue metastases to detect recurrent or metastatic prostate cancer; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In the therapeutic space, Lantheus provides AZEDRA, a radiopharmaceutical treatment for both adult and pediatric patients, and RELISTOR, a medication addressing opioid-induced constipation. The company's robust development pipeline includes promising innovations such as flurpiridaz F 18, an agent for assessing myocardial blood flow; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in both children and adults; PYLARIFY AI, an AI-powered medical device software for standardized quantitative analysis of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. Lantheus serves a diverse client base, including radiopharmacies, distributors, integrated delivery networks, hospitals, clinics, and group medical practices. They foster strategic collaborations with notable industry partners such as NanoMab Technology Limited, Bausch Health Companies, Inc., GE Healthcare Limited, Curium, Bayer AG, CytoDyn Inc., ROTOP, FUJIFILM, Regeneron Pharmaceuticals, Inc., and POINT Biopharma US Inc. Established in 1956, Lantheus Holdings, Inc. maintains its corporate headquarters in North Billerica, Massachusetts.

Bedford, MA

1,193 employees

www.lantheus.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Mary Anne Heino

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	1.56B	388.18M	377.33M	406.79M	384.01M	378.05M	372.76M	391.11M	378.73M
Cost of Goods Sold	620.29M	146.32M	146.41M	165.91M	161.65M	137.03M	135.06M	142.56M	136.61M
Gross Profit	936.02M	241.85M	230.92M	240.88M	222.37M	241.01M	237.70M	248.54M	242.13M
Gross Profit Margin	60.1%	62.3%	61.2%	59.2%	57.9%	63.8%	63.8%	63.5%	63.9%
Total Operating Expenses	633.68M	141.64M	149.60M	163.69M	178.75M	153.04M	135.63M	134.67M	108.38M
Research & Development	173.09M	38.20M	39.38M	47.48M	48.02M	45.49M	36.31M	35.33M	24.15M
Selling, General & Administrative	460.59M	103.44M	110.22M	116.21M	130.73M	107.56M	99.32M	101.51M	84.23M
Operating Income (EBIT)	302.34M	100.22M	81.33M	77.18M	43.62M	87.97M	102.07M	113.87M	133.74M
Operating Margin	19.4%	25.8%	21.6%	19.0%	11.4%	23.3%	27.4%	29.1%	35.3%
Income Before Tax (EBT)	362.98M	93.83M	156.41M	70.36M	42.38M	104.52M	96.53M	-783K	176.12M
Interest Income	11.66M	N/A	4.97M	3.07M	3.62M	7.21M	9.48M	9.56M	9.80M
Interest Expense	19.81M	4.92M	4.86M	5.08M	4.95M	4.92M	4.80M	5.04M	4.90M
Other Income/Expense	60.64M	-6.39M	75.08M	-6.82M	-1.23M	16.55M	-5.54M	-114.66M	42.38M
Net Income	275.31M	75.03M	118.42M	54.09M	27.77M	78.75M	72.94M	-11.79M	131.09M
Income Tax Expense	87.67M	18.80M	37.99M	16.28M	14.61M	25.76M	23.58M	11.01M	45.02M
Net Profit Margin	17.7%	19.3%	31.4%	13.3%	7.2%	20.8%	19.6%	-3.0%	34.6%
EBITDA	384.95M	116.92M	104.01M	100.00M	64.02M	101.20M	115.69M	131.16M	150.82M
EBITDA Margin	24.7%	30.1%	27.6%	24.6%	16.7%	26.8%	31.0%	33.5%	39.8%
Depreciation & Amortization	82.61M	16.70M	22.68M	22.82M	20.41M	13.23M	13.63M	17.29M	17.07M
EPS Basic	4.21	1.15	1.83	0.82	0.41	1.15	1.06	-0.17	1.89
EPS Diluted	4.14	1.11	1.80	0.82	0.41	1.12	1.02	-0.17	1.79
Weighted Average Basic Shares	65.16M	65.16M	64.74M	65.58M	67.23M	68.52M	68.67M	69.22M	69.46M
Weighted Average Diluted Shares	67.52M	67.52M	65.77M	66.31M	67.66M	70.31M	71.46M	69.22M	73.06M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	1.54B	1.53B	1.30B	935.06M	425.21M	339.41M	347.34M	343.37M
Cost of Goods Sold	599.66M	545.62M	586.89M	353.36M	237.51M	200.65M	172.53M	168.49M
Gross Profit	941.95M	988.29M	709.54M	581.70M	187.69M	138.76M	174.81M	174.88M
Gross Profit Margin	61.1%	64.4%	54.7%	62.2%	44.1%	40.9%	50.3%	50.9%
Total Operating Expenses	631.12M	531.31M	344.90M	545.51M	248.52M	142.96M	123.15M	110.40M
Research & Development	177.31M	168.10M	77.71M	311.68M	44.97M	32.79M	20.02M	17.07M
Selling, General & Administrative	453.81M	371.63M	267.19M	233.83M	218.82M	110.17M	103.13M	93.33M
Operating Income (EBIT)	310.83M	456.98M	364.64M	36.20M	-60.83M	-4.20M	51.66M	64.49M
Operating Margin	20.2%	29.8%	28.1%	3.9%	-14.3%	-1.2%	14.9%	18.8%
Income Before Tax (EBT)	313.79M	430.98M	410.94M	26.72M	-75.04M	-11.48M	28.63M	49.55M
Interest Income	23.39M	36.84M	19.64M	2.61M	45K	238K	686K	167K
Interest Expense	19.75M	19.67M	20.02M	7.18M	7.75M	9.48M	13.62M	17.41M
Other Income/Expense	2.96M	-26.00M	46.30M	-9.48M	-14.21M	-7.28M	-23.03M	-14.94M
Net Income	233.56M	312.44M	326.66M	28.07M	-71.28M	-13.47M	31.67M	40.52M
Income Tax Expense	80.23M	118.53M	84.28M	-1.35M	-3.76M	1.99M	-3.04M	9.03M
Net Profit Margin	15.2%	20.4%	25.2%	3.0%	-16.8%	-4.0%	9.1%	11.8%
EBITDA	380.93M	521.60M	424.69M	84.12M	-18.54M	20.49M	65.04M	78.35M
EBITDA Margin	24.7%	34.0%	32.8%	9.0%	-4.4%	6.0%	18.7%	22.8%
Depreciation & Amortization	70.10M	64.62M	60.04M	47.93M	42.29M	24.69M	13.38M	13.86M
EPS Basic	3.46	4.52	4.79	0.41	-1.06	-0.25	0.81	1.06
EPS Diluted	3.41	4.36	4.65	0.40	-1.06	-0.25	0.79	1.03
Weighted Average Basic Shares	67.49M	69.20M	68.27M	68.49M	67.49M	54.13M	38.99M	38.23M
Weighted Average Diluted Shares	68.44M	71.65M	70.24M	70.67M	67.49M	54.13M	40.11M	39.50M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.